Novartis CEO says 'dont expect' Prexige approval
Novartis CEO Daniel Vasella says it is unlikely that his companys Prexige (lumiracoxib) painkiller will gain FDA approval after being pulled from the market in Australia earlier this year due to safety concerns.
Your Email Address:
Recipient(s) Email Address:
(Separate multiple e-mail addresses with commas. Limited to 20 addresses.)
Include a message (optional):
The e-mail address(es) that you supply to use this service will only be used to send the requested article.